ETM Experimental and Therapeutic Medicine 1792-0981 1792-1015 D.A. Spandidos 10.3892/etm.2016.3438 ETM-0-0-3438 Articles Risk factors associated with secondary hyperparathyroidism in patients with chronic kidney disease WeiYudan 1 * LinJing 2 * YangFan 3 LiXiujiang 4 HouYue 1 LuRonghua 5 ShiXiaonv 1 LiuZhi 1 DuYujun 1 Department of Nephrology, First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Department of Nephrology, The First Affiliated Hospital of Luohe Medical College, Luohe, Henan 462000, P.R. China Reproductive Center of the First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China Department of Intensive Care Unit, Jilin Tumor Hospital, Changchun, Jilin 130021, P.R. China Department of Nephrology, Jilin City Central Hospital, Changchun, Jilin 132000, P.R. China Correspondence to: Dr Yujun Du, Department of Nephrology, First Hospital of Jilin University, 71 Xinmin Street, Changchun, Jilin 130021, P.R. China, E-mail: kjkduyujun@126.com

Contributed equally

 08 2016 08 06 2016 12 2 1206 1212 31032015 29042016 Copyright © 2016, Spandidos Publications 2016

Secondary hyperparathyroidism (SHPT) is common in patients with chronic kidney disease (CKD), and its development and progression are affected by various factors. The aim of the present study was to identify the risk factors for SHPT in patients with CKD. A retrospective study was performed in 498 patients (305 males and 193 females) with CKD, observed in the The First Hospital of Jilin University between January 2008 and December 2012. The demographic, clinical and laboratory data were collected. Patients were divided into the SHPT group (n=424) with elevated serum parathyroid hormone (PTH) expression levels and the control group (n=74) with normal serum PTH expression levels. Univariate and multivariate regression analyses were employed to explore the risk factors for SHPT. Serum PTH expression levels in women with CKD were significantly higher than in men (P=0.047). Serum PTH expression levels were positively correlated with the expression levels of serum creatinine (P<0.01), phosphorus (P<0.01), C-reactive protein (P<0.05), triglyceride (P<0.05), cholesterol (P<0.05) and low-density lipoprotein cholesterol (P<0.05), but were negatively correlated with the expression levels of hemoglobin (P<0.05), calcium (P<0.01) and CO2 combining power (P<0.01) in patients with CKD. Multivariate analysis showed that the serum expression levels of creatinine [µmol/l; odds radio (OR), 1.003; 95% confidence interval (CI), 1.002–1.004; P=0.001] and phosphorus (mmol/l; OR, 2.19; 95% CI, 1.254–3.826; P=0.006) in patients with CKD significantly influenced serum PTH expression levels. The SHPT risk factors include female gender, low calcium, high phosphorus, acidosis, anemia, hypertension, hyperlipidemia and micro-inflammation, with blood phosphorus and creatinine being independent risk factors.

 chronic kidney disease secondary hyperparathyroidism risk factor phosphorus creatinine Introduction

The incidence of chronic kidney disease (CKD) is rapidly increasing, posing a serious health problem worldwide. More than 16 million adults are affected by end stage CKD in the USA (1,2). Abnormal serum calcium, phosphorus and parathyroid hormone (PTH) expression levels are common challenges in the management of CKD (3,4). These biochemical abnormalities, together with the dysregulation of vitamin D metabolism and bone turnover, constitute a systemic syndrome termed CKD mineral and bone disorder (CKD-MBD) (5).

Secondary hyperparathyroidism (SHPT) is a common complication of patients with CKD, which is characterized by increased blood PTH levels, and abnormal mineral and bone metabolism (6). It is associated with increased morbidity and mortality, and adversely influences the quality of life of patients with CKD (3,6). The incidence of SHPT is reported to increase with the stage of CKD: 40% in stage 3, 70% in stage 4 and >80% in stage 5 (4,7).

The kidneys are vital organs regulating calcium and phosphorous homeostasis (8). SHPT is an adaptive pathophysiological process in response to deteriorating renal insufficiency (6). The fundamental mechanism of PTH in kidneys is to suppress the reabsorption of phosphate in the proximal tubule, and to stimulate calcium reabsorption in the ascending loop of Henle, distal tubule and collecting tubule (8). Upon the stimulation of PTH, renal calcium reabsorption and phosphate excretion are increased (9). Renal insufficiency leads to the dysregulation of calcium and phosphorous homeostasis, and results in reduced renal phosphate excretion and increased fibroblast growth factor-23 (FGF-23); the latter is a hormone that is primarily secreted by osteoblasts and osteocytes (10,11). FGF-23 regulates circulating phosphate by decreasing sodium phosphate co-transporters in the proximal tubule of the kidneys. It also blocks the synthesis of serum vitamin D by inhibiting the expression of 25-dihydroxyvitamin D3 1α hydroxylase (1,25-(OH)2D3) in the kidneys (12). These alterations further stimulate the production of PTH and hyperplasia of the parathyroid. In turn, these changes cause increasingly severe impairment of calcium and phosphorous metabolisms (13). If not properly managed, progressive SHPT can have severe consequences, and may lead to multi-system damages and malfunction of multiple organs that can result in bone disease, soft tissue calcification, vascular calcification and mortality (6).

The development and progression of SHPT is influenced by various factors. In addition to the well-recognized risk factors of impaired calcium and phosphorus metabolism and reduced 1,25-(OH)2D3 expression levels, numerous other factors have been implicated, such as anemia, acidosis, co-morbidities of cardiovascular disease and diabetes, and inflammation (6). In addition, SHPT itself is a risk factor for these pathophysiological conditions. Elevated PTH is associated with a greater prevalence and incidence of cardiovascular disease, and is an important cardiovascular disease risk factor (14). However, the complex interactions of these risk factors with SHPT remain unclear. In the current retrospective study, a large cohort of patients were recruited in order to analyze the association between risk factors influencing SHPT in patients with CKD, with a particular emphasis on laboratory biochemical measures. Early identification of risk factors could help prevent and treat SHPT in patients with CKD.

 Materials and methods <sec> <title>Patients

The study protocol was reviewed and approved by the Institutional Review Committees of the First Hospital of Jilin University, Changchun, China. The data from 498 consecutive cases of CKD enrolled in The First Hospital of Jilin University between January 2008 and December 2012 was extracted and reviewed. Patients aged 10–74 years with an age-stratified estimated glomerular filtration rate of 20–70 ml/min/1.73 m2 were included in the study. The inclusion criteria were as follows: i) Aged ≥18 years and met the clinical practice guideline for chronic kidney disease [kidney disease outcome quality initiative (K/DOQI)] (15); ii) have complete laboratory measurements; and iii) cases with primary hyperparathyroidism were excluded from the study. The exclusion criteria included: i) Use of ossification, calcium or phosphorus in the past 3 months; ii) history of bleeding or transfusion in the past 3 months; iii) severe infection in the past 3 months; and iv) history of human immunodeficiency virus infection, primary liver disease, cancer or autoimmune diseases.

 Study design

Demographic and clinical data were extracted from all patients with a confirmed diagnosis of CKD, including age, gender, body mass index, history of hypertension, diabetes, primary disease and other clinical data. Laboratory values were also collected from all patients with CKD. Based on serum PTH expression levels, the patients were divided into two groups: The SHPT group with elevated PTH expression levels (>88 pg/ml) and the control group with normal PTH expression levels (<88 pg/ml).

 Laboratory measures

After overnight fasting, blood samples were drawn using uniform techniques during the early morning in The First Hospital of Jilin University. The laboratory measurements included serum creatinine, hemoglobin (Hb), carbon dioxide combining power (CO2CP), triglyceride (TG), cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), serum albumin, serum calcium and phosphorus. CRP was detected using a turbidimetric immunoassay method (Siemens BN II; Siemens AG, Berlin, Germany). PTH was detected using a chemiluminescence method using Beckman DXI800 (Beckman Coulter, Inc., Indianapolis, IN, USA). 24 h urinary protein was detected using a pyrogallol red molybdate complex method (16). Serum PTH, calcium and phosphorus levels were measured using methods described previously (17). Hb levels were determined using sodium dodecyl sulfate hemoglobin determination (18). Other laboratory values were measured by standard methods according to the manufacturer's protocol using an auto analyzer (Hitachi 7600-210; Hitachi, Ltd., Tokyo, Japan).

 Statistical analysis

SPSS version 19.0 software (IBM SPSS, Armonk, NY, USA) was used for all statistical analyses. Results are presented as the mean ± standard deviation for continuous variables. Student's t-test was used for comparisons between two groups with normal distributions, and the Wilcoxon-Mann-Whitney U test was used for groups with non-normal distributions. χ2 test was used to analyze the differences between categorical data. Linear correlation analysis was performed to examine the association between serum PTH expression levels and the expression levels of other laboratory parameters; Pearson's correlation coefficients are presented. Multivariate logistic regression analysis was used to analyze the risk factors for SHPT. P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Patient characteristics

A total of 498 patients with a confirmed diagnosis of CKD were included in this retrospective study, including 305 males and 193 females (male to female ratio, 1.58:1). The mean age was 49.75 years (40–59 years). There were 424 patients with elevated PTH expression levels and 74 patients with normal serum PTH expression levels. The main causes of CKD were primary glomerular disease (53.61%), diabetic nephropathy (16.67%), hypertensive nephropathy (8.84%), chronic interstitial nephritis (7.03%), polycystic kidney (3.41%) and others (10.44%). The co-morbid conditions included hypertension (83.13%) and diabetes mellitus (16.67%).

 Comparisons of demographic and clinical characteristics between patients with normal PTH and elevated PTH expression levels

The differences in demographic and clinical characteristics between the normal PTH and elevated PTH groups in patients with CKD were compared and the results are presented in Table I. The age distribution had no significant difference between the control and SHPT groups (51.26±15.74 vs. 49.45±16.33 years; P=0.476). However, the difference in gender between the two groups was significant (P=0.047); 71.62% were male in the normal PTH group and 59.43% were male in the SHPT group. Female patients accounted for 28.38 and 40.57% in the two groups, respectively, indicating that increased PTH occurred more frequently in women than in men.

Primary underlying diseases had no significant effect on PTH expression levels (P=0.445). The disease distributions were similar in the control and SHPT groups: Primary glomerular diseases (55.41 vs. 53.30%), diabetic nephropathy (2.70 vs. 7.31%), hypertensive nephropathy (16.2 vs. 16.5%) and chronic interstitial nephritis (10.8 vs. 8.49%). The presence of co-morbid hypertension was significantly different between the two groups (73.00 vs. 84.9%; P<0.05; Table I)

 Comparisons of laboratory biochemical markers between patients with normal and elevated PTH expression levels

The differences in the laboratory biochemical measurements between the two groups were analyzed. Compared with the control group, the mean serum expression levels of creatinine, CRP, TG, TC and LDL-C were significantly increased, and the mean levels of hemoglobin and CO2CP were significantly decreased, in the elevated PTH group (all P<0.05). However, the values of serum albumin and 24 h urinary protein were not significantly different between the two groups (P>0.05). Compared with the normal PTH group, the mean calcium levels were significantly decreased and the mean phosphorus levels were significantly increased in patients with elevated PTH expression levels (both P<0.01; Table II)

 Multivariate analysis of risk factors influencing SHPT

A multivariate logistic regression analysis was performed in order to identify independent factors of SHPT. The results demonstrated that the serum creatinine [µmol/l; odds radio (OR), 1.003; 95% confidence interval (CI), 1.002–1.004; P=0.001) and serum phosphorus (mmol/l; OR, 2.19; 95% CI, 1.254–3.826; P=0.006) were independent risk factors for SHPT (Table III).

 Correlation analysis of serum PTH expression levels with biochemical markers in patients with CKD

Correlation analyses were performed in order to analyze the associations between serum PTH with laboratory biochemical measurements in patients with CKD. As presented in Table IV, the results indicated that serum PTH expression levels were positively correlated with the expression levels of serum creatinine (P<0.01), phosphorus (P<0.01), CRP (P<0.001), TG (P<0.001), TC (P<0.001) and LDL-C (P=0.011), and negatively correlated with the expression levels of blood hemoglobin (P=0.025), calcium (P<0.001) and CO2CP (P<0.001). There were no significant correlations between the PTH expression levels and serum albumin, HDL-C or 24 h urinary protein in these patients (P>0.05; Table IV).

 Discussion

SHPT is a progressive and severe complication frequently associated with CKD. The development and progression is affected by several factors associated with various mechanisms (6). To determine the risk factors of SHPT in patients with CKD, a retrospective study with a large cohort of patients who were clinically diagnosed with CKD was conducted. The elevated serum PTH expression levels were shown to be positively correlated with the severity of hyperparathyroidism. Based on serum PTH expression levels, patients were divided into normal PTH and elevated PTH expression level groups. For patients with elevated PTH expression levels, primary hyperparathyroidism cases were excluded prior to enrollment in the study. The present study demonstrated that 85.14% patients with CKD had elevated serum PTH expression levels, which was similar to that in previous reports (7,19). Andress et al (7) reported that ~40% patients with CKD stage 3 and 80% of patients with CKD stage 4 are affected by SHPT. Drüeke (19) reported that SHPT is observed in 20–80% patients with CKD, depending on the stages of the disease.

In the present study, it was observed that elevated PTH was more commonly observed in women compared with men, suggesting that there is a significant gender difference in PTH elevation. A previous study suggested that the elevated estrogen and estrogen receptor expression levels upregulate the mRNA expression levels of PTH in parathyroid cells (20), which may explain the gender difference in the development of SHPT.

Among the underlying diseases causing CKD, primary glomerulonephritis remains the leading cause of CKD (21). The disease accounted for 53.61% of the cases in the present study, which is similar to previous studies that reported 55% (3,4). Hypertension is a risk factor of CKD and also a common complication of CKD (22,23). With the progression of CKD, 80–85% patients have elevated blood pressure. The current study demonstrated that 83.14% patients with CKD had hypertension, and the majority of these hypertensive patients had SHPT. A previous study (24) has suggested that elevation of PTH expression levels in patients with end-stage kidney disease increases cytoplasmic calcium concentration in vascular smooth muscle cells and thereby promotes vessel contraction. The enhanced resistance of peripheral vessel increases blood pressure. In turn, hypertension stimulates the secretion of PTH and promotes the progression of secondary hyperparathyroidism. This cycle accelerates the deterioration of renal insufficiency.

Blood phosphorus expression levels are one of the most important factors stimulating the synthesis and secretion of PTH in patients with CKD (25). With worsening renal function, the excretion of phosphorus from renal tubular decreases and blood phosphorus levels increase (25). The results from the present study demonstrated that hyperphosphatemia was an independent risk factor influencing the development of SPTH. Voormolen et al (26) reported that elevated plasma phosphorus directly stimulates the synthesis and secretion of PTH in patients with stage 4–5 CKD. The effect of plasma phosphorus is independent of the level of plasma calcium or the activation of vitamin D. The results in the current study were in line with this report, indicating that hyperphosphatemia is an independent risk factor affecting renal function in patients with CKD.

Blood calcium expression levels are another important factor affecting PTH in patients with CKD (27). In the present study, univariate analyses showed that the blood calcium expression levels were significantly lower in patients with elevated PTH expression levels compared with in patients with normal PTH expression levels (P<0.05). Unlike the plasma phosphorus expression levels, the plasma calcium expression levels were not an independent risk factor for the elevation of PTH.

Serum creatinine expression levels are a commonly used index indirectly assessing the renal function of patients, and the rising of serum creatinine predicts the worsening of renal function (28). According to the K/DOQI guidelines (15), once the glomerular filtration rate of patients with CKD is <60 ml/min, PTH expression levels increase and calcium expression levels decrease. Previous reports (15,29) have suggested that PTH elevation is negatively correlated with the reduction of the glomerular filtration rate. The results of the present study demonstrated that PTH is negatively correlated with serum creatinine expression levels in patients with CKD. In addition, multivariate analysis revealed that serum creatinine expression levels are an independent risk factor for SHPT. Metabolic acidosis is common in patients with chronic renal insufficiency. Due to the decline of hydrogen excretion or HCO3 reabsorption in renal tubular, phosphoric acid, sulfuric acid and other acidic substances are retained inside the body (30,31). Acidosis inhibits the activity of 1-α hydroxylase in the proximal tubule, and thereby inhibits the synthesis of 1,25-(OH)2D3. Disthabanchong et al (32) suggested that metabolic acidosis promotes the response to PTH in UMR 106-01 osteoblast-like cells, and that the effect is mediated by increasing the mRNA expression levels of the PTH/PTHrP receptor.

The C reactive protein is the most recognized inflammatory protein (33) and has been widely used to monitor the inflammatory responses in patients. Previous studies have suggested that microinflammation exists in patients with CKD (34,35); with the deterioration of renal insufficiency, microinflammation increases, resulting in glomerular sclerosis and the weakening of renal tubular elasticity. The release of various inflammatory mediators further promote the proliferation of glomerular mesangial cells, increase endothelial cell permeability, stimulate the production of white blood cells, and promote the release of superoxide and proteolytic enzymes (34,35). These changes further deteriorate renal function and aggravate the elevation of PTH (36).

Renal anemia is a common complication of CKD. The incidence of renal anemia increases significantly following stage 3 CKD (37). The severity of anemia indirectly reflects renal dysfunction. In the present study, it was observed that the serum PTH expression levels were negatively correlated with blood hemoglobin expression levels in patients with CKD. PTH is considered to be a uremic toxin, as it directly inhibits the hematopoietic function of bone marrow, increases the fragility of erythrocytes and shortens the life expectancy of erythrocytes (38). SHPT can also increase erythropoietin resistance (39). In addition, SHPT-induced bone damage results in the proliferation of fibroblasts and fibrosis of bone marrow, leading to secondary anemia (40). These mechanisms likely underlie the frequently occurring anemia in patients with CKD.

Abnormal lipid metabolism is common in patients with CKD, and is the most important risk factor for CKD-associated cardiovascular disease (41). In addition, lipid deposition has a direct toxic effect on renal function (42). Previous reports suggest that, in addition to proteinuria and hypertension, hyperlipidemia is the third important risk factor for CKD (43). Abnormal lipid metabolism and deposition are associated with microinflammation and oxidative stress (44). The current study demonstrated that PTH is positively correlated with the expression levels of serum TG, TC and LDL-C in patients with CKD, suggesting that hyperlipidemia is closely associated with SHPT.

Whereas previous studies have primarily focused on the analysis of traditional risk factors of SHPT, the current study analyzed multiple factors influencing the occurrence and development of SHPT (25,45,46). However, this retrospective study had a number of limitations. The selected patients were in different stages of renal insufficiency, which may influence the results of analysis. In addition, the sample size of the normal PTH expression level group was relatively small, which may have an impact on the correlation analyses.

In conclusion, the development of SHPT in patients with CKD is affected by numerous risk factors, including female gender, low expression levels of calcium, high expression levels of phosphorus, acidosis, anemia, hypertension, hyperlipidemia and C reactive protein. Serum phosphorus and serum creatinine are independent risk factors for SHPT. SHPT is likely to be the result of complex interactions among these factors. Early identification of the risk factor is beneficial to the prevention and treatment of CKD.

 Acknowledgements

The authors thank Medjaden Bioscience Limited for assisting in the preparation of the manuscript.

 Abbreviations SHPT

secondary hyperparathyroidism

 CKD

chronic kidney disease

 PTH

parathyroid hormone

 Hb

hemoglobin

 CO2CP

carbon dioxide combining power

 TG

triglyceride

 TC

cholesterol

 HDL-C

high-density lipoprotein cholesterol

 LDL-C

low-density lipoprotein cholesterol

 CRP

C-reactive protein

 MBD

mineral and bone disorder

 FGF-23

fibroblast growth factor-23

 PTHrP

parathyroid hormone-related protein

 EPO

erythropoietin

 References CoreshJSelvinEStevensLAManziJKusekJWEggersPVan enteFLeveyASPrevalence of chronic kidney disease in the United StatesJAMA29820382047200710.1001/jama.298.17.203817986697 Centers for Disease Control and Prevention: Prevalence of chronic kidney disease and associated risk factors - United States, 1999–2004MMWR Morb Mortal Wkly Rep56161165200717332726 MelamedMLEustaceJAPlantingaLJaarBGFinkNECoreshJKlagMJPoweNRChanges in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal studyKidney Int70351357200610.1038/sj.ki.500154216738536 LevinABakrisGLMolitchMSmuldersMTianJWilliamsLAAndressDLPrevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney diseaseKidney Int713138200710.1038/sj.ki.500200917091124 MoeSDrüekeTCunninghamJGoodmanWMartinKOlgaardKOttSSpragueSLameireNEknoyanGKidney Disease: Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney Int6919451953200610.1038/sj.ki.500041416641930 CunninghamJLocatelliFRodriguezMSecondary hyperparathyroidism: Pathogenesis, disease progression, and therapeutic optionsClin J Am Soc Nephrol6913921201110.2215/CJN.0604071021454719 AndressDLCoyneDWKalantar-ZadehKMolitchMEZangenehFSpragueSMManagement of secondary hyperparathyroidism in stages 3 and 4 chronic kidney diseaseEndocr Pract141827200810.4158/EP.14.1.1818238737 FukagawaMHamadaYNakanishiSTanakaMThe kidney and bone metabolism: Nephrologists' point of viewJ Bone Miner Metab24434438200610.1007/s00774-006-0719-717072734 LiJMolnarMZZaritskyJJSimJJStrejaEKovesdyCPSaluskyIKalantar-ZadehKCorrelates of parathyroid hormone concentration in hemodialysis patientsNephrol Dial Transplant2815161525201310.1093/ndt/gfs59823348879 LiuSGuoRSimpsonLGXiaoZSBurnhamCEQuarlesLDRegulation of fibroblastic growth factor 23 expression but not degradation by PHEXJ Biol Chem2783741937426200310.1074/jbc.M30454420012874285 RiminucciMCollinsMTFedarkoNSChermanNCorsiAWhiteKEWaguespackSGuptaAHannonTEconsMJFGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wastingJ Clin Invest112683692200310.1172/JCI1839912952917 ShimadaTHasegawaHYamazakiYMutoTHinoRTakeuchiYFujitaTNakaharaKFukumotoSYamashitaTFGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasisJ Bone Miner Res19429435200410.1359/JBMR.030126415040831 SlatopolskyEBrownADussoAPathogenesis of secondary hyperparathyroidismKidney Int Suppl73S73S14S19199910.1046/j.1523-1755.1999.07304.x10633458 AndersonJLVanwoerkomRCHorneBDBairTLMayHTLappéDLMuhlesteinJBParathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors?Am Heart J162331339.e2201110.1016/j.ahj.2011.05.00521835295 National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney diseaseAm J Kidney Dis424 Suppl 3S1S201200314520607 OrsonneauJLDouetPMassoubreCLustenbergerPBernardSAn improved pyrogallol red-molybdate method for determining total urinary proteinClin Chem352233223619892582622 MoeSMChertowGMCoburnJWQuarlesLDGoodmanWGBlockGADrüekeTBCunninghamJSherrardDJMcCaryLCAchieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HClKidney Int67760771200510.1111/j.1523-1755.2005.67139.x15673327 KarsanAMaclarenIConnDWadsworthLAn evaluation of hemoglobin determination using sodium lauryl sulfateAmJ Clin Pathol100123126199310.1093/ajcp/100.2.123 DrüekeTBCell biology of parathyroid gland hyperplasia in chronic renal failureJ Am Soc Nephrol1111411152200010820180 PrinceRLCounterpoint: Estrogen effects on calcitropic hormones and calcium homeostasisEndocr Rev15301309199410.1210/edrv-15-3-3018076583 LiLSLiuZHEpidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsiesKidney Int66920923200410.1111/j.1523-1755.2004.00837.x15327382 TsaiWCWuHYPengYSKoMJWuMSHungKYWuKDChuTSChienKLRisk factors for development and progression of chronic kidney disease: A systematic review and exploratory meta-analysisMedicine (Baltimore)95e3013201610.1097/MD.000000000000301326986114 StaplesAWongCRisk factors for progression of chronic kidney diseaseCurr Opin Pediatrics22161169201010.1097/MOP.0b013e328336ebb0 FerrierKEMuhlmannMHBaguetJPCameronJDJenningsGLDartAMKingwellBAIntensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertensionJ Am Coll Cardiol3910201025200210.1016/S0735-1097(02)01717-511897445 HruskaKAMathewSThe roles of the skeleton and phosphorus in the CKD mineral bone disorderAdv Chronic Kidney Dis1898104201110.1053/j.ackd.2011.01.00121406294 VoormolenNNoordzijMGrootendorstDCBeetzISijpkensYWvan ManenJGBoeschotenEWHuismanRMKredietRTDekkerFWPREPARE study group: High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patientsNephrol Dial Transplant2229092916200710.1093/ndt/gfm28617517792 GoodmanWGQuarlesLDDevelopment and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular geneticsKidney Int74276288200810.1038/sj.ki.500228717568787 SmithGLShlipakMGHavranekEPFoodyJMMasoudiFARathoreSSKrumholzHMSerum urea nitrogen, creatinine, and estimators of renal function: mortality in older patients with cardiovascular diseaseArch Intern Med16611341142200610.1001/archinte.166.10.113416717177 Kidney Disease; Improving Global Outcomes (KDIGO)CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)Kidney Int76Suppl 113S1S1302009 OrtegaLMAroraSMetabolic acidosis and progression of chronic kidney disease: incidence, pathogenesis, and therapeutic optionsNefrologia32724730201223169354 KovesdyCPMetabolic acidosis and kidney disease: does bicarbonate therapy slow the progression of CKD?Nephrol Dial Transplant2730563062201210.1093/ndt/gfs29122851628 DisthabanchongSMartinKJMcConkeyCLGonzalezEAMetabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cellsKidney Int6211711177200210.1111/j.1523-1755.2002.kid568.x12234287 Lavín-GómezBAPalomar-FontanetRGago-FraileMQuintanar-LartundoJAGómez-PalomoEGonzález-LamuñoDGarcía-UnzuetaMTArias-RodríguezMAGómez-GeriqueJAInflammation markers, chronic kidney disease, and renal replacement therapyAdv Perit Dial273337201122073825 TsirpanlisGBagosPIoannouDBletaAMarinouILagouranisAChatzipanagiotouSNicolaouCExploring inflammation in hemodialysis patients: Persistent and superimposed inflammation. A longitudinal studyKidney Blood Press Res276370200410.1159/00007580914691348 OjedaRAljamaPAChronic microinflammation and endothelial damage in uremiaNefrologia285835862008(In Spanish)19016629 ShimadaKKawarabayashiTTanakaAFukudaDNakamuraYYoshiyamaMTakeuchiKSawakiTHosodaKYoshikawaJOolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery diseaseDiabetes Res Clin Pract65227234200410.1016/j.diabres.2004.01.00315331202 IsekiKKohaguraKAnemia as a risk factor for chronic kidney diseaseKidney Int SupplS4S9200710.1038/sj.ki.500248117943141 UrenaPEckardtKUSarfatiEZingraffJZinsBRoulletJBRolandEDrüekeTKurtzASerum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: Effect of parathyroidectomyNephron59384393199110.1159/0001865961758526 DrüekeTBEckardtKURole of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patientsNephrol Dial Transplant17Suppl 52831200210.1093/ndt/17.suppl_5.28 StrutzFZeisbergMRenal fibroblasts and myofibroblasts in chronic kidney diseaseJ Am Soc Nephrol1729922998200610.1681/ASN.200605042017035610 AttmanPOSamuelssonOAlaupovicPLipoprotein metabolism and renal failureAm J Kidney Dis21573592199310.1016/S0272-6386(12)80030-88503411 BobulescuIARenal lipid metabolism and lipotoxicityCurr Opin Nephrol Hypertens19393402201010.1097/MNH.0b013e32833aa4ac20489613 SandhuSWiebeNFriedLFTonelliMStatins for improving renal outcomes: A meta-analysisJ Am Soc Nephrol1720062016200610.1681/ASN.200601001216762986 MorenaMCristolJPSenécalLLeray-MoraguesHKrieterDCanaudBOxidative stress in hemodialysis patients: Is NADPH oxidase complex the culprit?Kidney Int Suppl61109114200210.1046/j.1523-1755.61.s80.20.x WilliamsMEChronic kidney disease/bone and mineral metabolism: the imperfect stormSemin Nephrol2997104200910.1016/j.semnephrol.2009.01.00219371800 BoverJAguilarABaasJReyesJLloretMJFarréNOlayaMCanalCMarcoHAndrésETrinidadPBallarinJCalcimimetics in the chronic kidney disease-mineral and bone disorderInt J Artif Organs32108121200919363783

Univariate analyses in patients with chronic kidney disease.

Control SHPT
Variable No. of patients % No. of patients % P-value
Total (n=498) 74 100 424 100
Age, years (mean ± SD) 51.26±15.74 49.45±16.33 0.476
Gender 0.047a
  Male 53 71.62 252 59.43
  Female 21 28.38 172 40.57
Underlying cause 0.445
  Primary glomerular diseases 41 55.41 226 53.30
  Diabetic nephropathy 2 2.70 31 7.31
  Hypertensive nephropathy 12 16.22 70 16.51
  Chronic interstitial nephritis 8 10.81 36 8.49
  Polycystic kidney 1 1.35 26 6.13
  Other 10 13.51 42 9.91
Co-morbid condition
  Hypertension 54 72.91 360 84.91 0.011a

P<0.05. P values were obtained from comparisons between the SHPT and control group. SHPT, secondary hyperparathyroidism; SD, standard deviation.

Univariate analyses of biochemical factors affecting SHPT in patients with chronic kidney disease.

Variable Controla SHPTa P-value
Serum albumin (g/dl) 32.59±7.56 31.48±6.47 0.189
Serum creatinine (µmol/l) 241.45±235.33 699.30±350.17 <0.001b
Blood hemoglobin (g/dl) 117±27.36 88.50±24.96 <0.001b
CO2CP (mmol/l) 23.73±4.22 21.04±4.96 <0.001b
C-reactive protein (g/l) 1.76±10.16 3.11±14.41 0.018c
Triglyceride (mmol/l) 1.23±1.14 1.58±0.92 0.024c
Cholesterol (mmol/l) 4.20±1.29 4.65±1.29 0.016c
LDL-C (mmol/l) 2.49±0.95 2.80±0.91 0.028c
HDL-C (mmol/l) 1.18±0.67 1.14±0.49 0.107
Urinary protein (g/24 h) 3±3.37 2.35±4.43 0.64
Calcium (mmol/l)   2.16±0.23 1.98±1.58 0.024c
Phosphorus (mmol/l) 1.48±0.42 1.88±0.62 <0.001b
PTH (pg/ml) 435.99±380.84 49.86±22.83 <0.001b

SHPT, secondary hyperparathyroidism; CO2CP, carbon dioxide combining power; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; PTH, parathyroid hormone.

Expressed as the mean ± standard deviation

P<0.01

P<0.05.

Multivariate analysis of risk factors influencing secondary hyperparathyroidism in 498 patients with chronic kidney disease.

95% CI
Variable Odds ratio Lower Upper P-value
Gender 1.561 0.836 2.916 0.162
Blood pressure 1.931 0.098 3.739 0.051
Hemoglobin 0.994 0.982 1.006 0.348
Serum creatinine 1.003 1.002 1.004 0.001a
Serum calcium 0.976 0.379 2.891 0.321
Serum phosphorus 2.190 1.254 3.826 0.006a
CO2CP 0.945 0.886 1.008 0.086
C-reactive protein 1.994 0.989 1.091 0.591
Triglyceride 0.926 0.689 1.244 0.608
Cholesterol 0.291 0.644 1.317 0.651
LDL-C 0.918 0.620 1.545 0.925

CI, confidence interval; CO2CP, carbon dioxide combining power; LDL-C, low-density lipoprotein cholesterol

P<0.01.

Correlation analysis of parathyroid hormone with biochemical markers in 498 patients with chronic kidney disease.

Variable R-value P-value
Serum creatinine 0.161 <0.001a
Phosphorus 0.632 <0.001a
C reactive protein 0.151 <0.001a
Triglyceride 0.193 <0.001a
Cholesterol 0.166 <0.001a
LDL-C 0.138 0.011b
Hemoglobin −0.285 0.025b
Calcium −0.825 <0.001a
CO2CP −0.232 <0.001a
Serum albumin −0.029 0.515
HDL-C −0.014 0.749
24 h urinary protein −0.120 0.107

LDL-C, low-density lipoprotein cholesterol; CO2CP, carbon dioxide combining power; HDL-C, high-density lipoprotein cholestrol.

P<0.01

P<0.05.